Washington, DC (February 27, 2023) – UsAgainstAlzheimer’s chair and co-founder George Vradenburg issued the following statement regarding the announcement that Dr. Billy Dunn, Director of the Office of Neuroscience at the Food and Drug Administration (FDA), will be retiring: 

“Dr. Dunn is a longtime champion of patient-focused drug development, and we applaud him for his commitment to addressing what matters most to Alzheimer’s patients with the urgency this huge unmet need requires. We thank Dr. Dunn for his bold leadership in making safe and effective Alzheimer’s treatments accessible to people living with this disease in a timely manner consistent with the scientific evidence. As the agency works to identify a permanent replacement, we hope they will select someone with deep knowledge and experience in Alzheimer’s and related Dementias who will make this disease a top priority.” 

About UsAgainstAlzheimer’s

UsAgainstAlzheimer’s is engaged in a relentless pursuit to end Alzheimer’s, the sixth leading killer in America. Our work centers on prevention, early detection and diagnosis, and access to treatments – all regardless of gender, race, or ethnicity. To achieve our mission, we give voice to patients and caregivers while partnering with government, scientists, the private sector, and allied organizations -- the people who put the “Us” in UsAgainstAlzheimer’s.